GeoVax Labs, a clinical-stage biotechnology company, will host a conference call on March 27, 2025, to discuss its financial performance and provide a comprehensive corporate update. The company will review its ongoing research in COVID-19 vaccines and oncology therapies.
The conference call, scheduled for 4:30 p.m. ET, will feature management presenting detailed financial results and insights into the company's key clinical programs. Of particular interest is the BARDA-funded Phase 2b clinical trial of GEO-CM04S1, a next-generation COVID-19 vaccine targeting immunocompromised patients and serving as a potential booster for those previously vaccinated.
In the oncology space, GeoVax will likely discuss its Gedeptin® therapy, which recently completed a Phase 1/2 clinical trial for advanced head and neck cancers. The company is planning a Phase 2 clinical trial evaluating Gedeptin® in combination with an immune checkpoint inhibitor for first recurrent head and neck cancer.
The call represents a critical opportunity for investors and stakeholders to gain insights into GeoVax's strategic direction, financial health, and potential breakthrough technologies in vaccine and cancer treatment research.
